Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bacteremia Sepsis Clear all
Completed Phase 2 Interventional

Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.

NCT00002192
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Rifapentine, Ethambutol hydrochloride, Clarithromycin, Azithromycin
Drug
Lead sponsor
Anderson Clinical Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Hampton, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 6:01 AM EDT
Completed Not applicable Interventional Results available

Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures

NCT01898208
View directory record Official record
Conditions
Bacteremia, Fungemia, Bloodstream Infection
Interventions
FilmArray testing, Antimicrobial Stewardship, Bacterial culture, Susceptibility testing
Device · Behavioral · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Up to 99 Years
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Jul 22, 2026, 6:01 AM EDT
Terminated Phase 4 Interventional Results available

Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)

NCT00638157
View directory record Official record
Conditions
Infective Endocarditis
Interventions
daptomycin, daptomycin and gentamicin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Denver, Colorado • Detroit, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Jul 22, 2026, 6:01 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia

NCT00695903
View directory record Official record
Conditions
Endocarditis, Bacterial, Infective Endocarditis
Interventions
daptomycin, vancomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Greenville, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 23, 2018 · Synced Jul 22, 2026, 6:01 AM EDT
Completed Not applicable Interventional Results available

Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes

NCT06069206
View directory record Official record
Conditions
Bloodstream Infection, Sepsis Bacterial, MRSA Bacteremia, Vancomycin
Interventions
T2Bacteria® Panel (direct-from-blood testing), Usual Care
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 22, 2026, 6:01 AM EDT
Completed Not applicable Interventional Results available

Prospective Study to Investigate the Frequency of Possible Bacterial Entry Into the Bloodstream (Bacteremia) and Infectious Complications Associated With the Use of the Spyglass Cholangioscopy System During ERCP (Endoscopic Retrograde Cholangiopancreatography).

NCT01414400
View directory record Official record
Conditions
Bile Duct Stricture, Choledocholithiasis
Interventions
Blood draw for culture
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Jul 22, 2026, 6:01 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia

NCT01701219
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia, Methicillin-resistant Staphylococcus Aureus (MRSA) Bacteremia
Interventions
Ceftaroline fosamil
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
27
States / cities
Birmingham, Alabama • Sacramento, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Jul 22, 2026, 6:01 AM EDT
Terminated Phase 4 Interventional Results available

Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation

NCT04673175
View directory record Official record
Conditions
Pneumonia, Hematologic Malignancy, Pseudomonas Aeruginosa Infection, Bacteremia, Hematopoietic Stem Cell Transplant (HSCT)
Interventions
Ceftolozane / Tazobactam Injection
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jul 22, 2026, 6:01 AM EDT
Completed No phase listed Observational

Comparison of Infection Rates Among Patients Using Two Catheter Access Devices

NCT00965198
View directory record Official record
Conditions
Catheter-Related Infections, Bacteremia
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Jul 22, 2026, 6:01 AM EDT
Active, not recruiting No phase listed Observational

Immune Resolution After Staphylococcus Aureus Bacteremia

NCT01879761
View directory record Official record
Conditions
Immune Response To Sepsis, Staphylococcus Aureus Infection
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 22, 2026, 6:01 AM EDT
Completed No phase listed Observational

Clinical Outcomes and Cost of Gram Negative Bacteremia

NCT02599220
View directory record Official record
Conditions
Gram-negative Bacteremia, Bacteremia
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Jul 22, 2026, 6:01 AM EDT
Completed No phase listed Observational

Piperacillin/Tazobactam for Bacteremia With Organisms Producing Chromosomally-Encoded AmpC Beta-Lactamase

NCT00414193
View directory record Official record
Conditions
Bacteremia, AmpC Beta-lactamase
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Jul 22, 2026, 6:01 AM EDT
Completed No phase listed Observational

Pharmacodynamic Parameters of Two Different Doses of Cefepime

NCT00177736
View directory record Official record
Conditions
Infection, Bacteremia, Pneumonia
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2007 · Synced Jul 22, 2026, 6:01 AM EDT
Completed No phase listed Observational Results available

Home Away From Home - Medical Outcomes

NCT02774850
View directory record Official record
Conditions
Acute Myeloid Leukemia, Neutropenia, Bacteremia
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 19 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
17
States / cities
Little Rock, Arkansas • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2019 · Synced Jul 22, 2026, 6:01 AM EDT
Not listed Phase 2 Interventional

Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections

NCT00057369
View directory record Official record
Conditions
Bacteremia
Interventions
dalbavancin
Drug
Lead sponsor
Vicuron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 6:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dietary Green Tea Confection For Resolving Gut Permeability-Induced Metabolic Endotoxemia In Obese Adults

NCT03413735
View directory record Official record
Conditions
Obesity, Endotoxemia, Inflammation
Interventions
Green Tea Extract, Placebo
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Jul 22, 2026, 6:01 AM EDT
Completed No phase listed Observational

Diagnosis of Bacteremia/Septicemia and Culture Negative Endocarditis by the Karius Sequencing-Based Infectious Disease Diagnostic Assay

NCT02988414
View directory record Official record
Conditions
Bacteremia, Septicemia
Interventions
Not listed
Lead sponsor
Karius, Inc.
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Jul 22, 2026, 6:01 AM EDT
Completed Phase 2 Interventional Results available

Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia

NCT03163446
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Interventions
CF-301, Placebo
Biological · Drug
Lead sponsor
ContraFect
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
31
States / cities
Birmingham, Alabama • Sacramento, California • Sylmar, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Jul 22, 2026, 6:01 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia

NCT04597242
View directory record Official record
Conditions
MRSA Bloodstream Infection, MRSA Bacteremia, MRSA Right-sided Endocarditis, Covid19
Interventions
Exebacase
Drug
Lead sponsor
ContraFect
Industry
Eligibility
18 Years and older
U.S. locations
2
States / cities
Butte, Montana • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Jul 22, 2026, 6:01 AM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients

NCT01734694
View directory record Official record
Conditions
Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis, Endocarditis, Bacteremia, Acute Bacterial Skin and Skin Structure Infections
Interventions
Vancomycin, Ceftaroline, Daptomycin, Linezolid
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Jul 22, 2026, 6:01 AM EDT
Completed Phase 2 Interventional Results available

Lipid Infusion in Dialysis Patients With Endotoxemia

NCT00506454
View directory record Official record
Conditions
Fatigue, End Stage Renal Disease (ESRD)
Interventions
Lipidose, Placebo
Drug
Lead sponsor
Sepsicure
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Jul 22, 2026, 6:01 AM EDT
Terminated No phase listed Observational

Procalcitonin Levels as a Predictor of Bacteremia in Febrile Pediatric Oncology Patients-Pilot Study

NCT02417168
View directory record Official record
Conditions
Cancer, Bacteremia
Interventions
Not listed
Lead sponsor
CAMC Health System
Other
Eligibility
Up to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Jul 22, 2026, 6:01 AM EDT
Completed No phase listed Observational

Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock

NCT01867905
View directory record Official record
Conditions
Severe Sepsis, Septic Shock, Bacteremia
Interventions
Not listed
Lead sponsor
University of British Columbia
Other
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jul 22, 2026, 6:01 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.

NCT02357966
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
514G3 (2 mg/kg) plus standard IV antibiotic treatment, 514G3 (10 mg/kg) plus standard IV antibiotic treatment, 514G3 (40 mg/kg) plus standard IV antibiotic treatment, Placebo plus standard IV antibiotic treatment, 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II, Placebo plus standard IV antibiotic treatment: Phase II
Biological · Other
Lead sponsor
XBiotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Columbus, Georgia • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jul 22, 2026, 6:01 AM EDT